menu
techminis

A naukri.com initiative

google-web-stories
Home

>

Bio News

>

Engineerin...
source image

Bioengineer

7d

read

370

img
dot

Image Credit: Bioengineer

Engineering Immune Cells to Fight Cancer

  • Researchers are focusing on innate immune cells like NK cells, macrophages, and γδ T cells for cancer immunotherapy due to their intrinsic antitumor activity and rapid immune activation.
  • NK cells, known for their ability to detect and destroy transformed cells without antigen presentation, face challenges like limited in vivo persistence and tumor microenvironment immunosuppression.
  • Macrophages play a critical role in engulfing cancer cells but often become polarized into protumoral phenotypes within tumors, hindering tumor eradication.
  • Innovative engineering approaches, including CAR technology and signaling pathway modulation, aim to reprogram tumor-associated macrophages for a tumoricidal effect.
  • γδ T cells exhibit rapid response abilities and potent cytotoxicity, but their rarity and functional heterogeneity present barriers to therapeutic exploitation.
  • Advanced genetic engineering techniques are being used to design innate immune cells with enhanced antitumor efficacy, leveraging CRISPR editing, CAR constructs, and cytokine armoring.
  • Challenges in translating engineered innate immune cells to clinical use include ex vivo expansion complexities, tumor microenvironment immunosuppression, and safety concerns.
  • Preclinical studies show promising outcomes with engineered innate immune cells, such as CAR-NK cells and macrophages, in mediating antitumor responses.
  • Clinical trials with CAR-NK cells and macrophage-based therapies are showing initial clinical efficacy, signaling a new era in immuno-oncology.
  • Obstacles to routine clinical integration include manufacturing complexities, personalized therapy approaches, and rigorous monitoring for adverse events.
  • The fusion of synthetic biology with innate immune engineering offers potential for more flexible, durable, and controlled cancer therapies through modular receptor platforms and multifactorial synergy.

Read Full Article

like

22 Likes

For uninterrupted reading, download the app